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Academic drug discovery in Europe
Drug Discovery Living with Failure
All figs from Munos 2009 Nature Drug Discovery
One solution to constant NME output:
Harness the ‘global brain’ to access the best science and ideas
wherever they may be. Such open architecture for R&D has key
advantages: it heightens competition, reduces costs and increases
agility by making it easier to initiate and terminate projects. More
importantly, it makes it easier to manage ‘disruptive innovation’ by
locating it outside the corporate walls (Munos 2009),
The innovation gap updated
Top level figures
• 4300 companies involved in R+D 
• 261 organizations = 1,222 NMEs. (6% of all companies)
• 21 companies = ~600 NMEs.
• 70% Pharma mergers reduce NME output
• Small company (not top 15) success rate < 0.1 NME pa
Industry response to the innovation gap
Data and IP pooling New collaboration models        Talking the talk
> 70 Screening Centres
Frearson and Collie 2009
Clinical and Translational 
Science Centres USA
Planned 60 centres
> $500 million
of NIH funds
Initiatives in Europe
http://www.ncrr.nih.gov/
http://imi.europa.eu
http://www.eatris.eu/
http://www.eu-
openscreen.eu/
Academic Initiatives in Drug Discovery
Lead Finding in Big Pharma
European Academic Screening 
Centres – 2011 figures
European, approx 27% of the total  (64% USA) Typically cover all main target classes
For all centres, average of 13 targets p/a Most centres screen < 1 million wells per year
All figures courtesy of John Comley - HTStec’s ‘Academic Outreach and Screening Trends 2011’ Report 
Regional and centralised drug 
discovery facilities
•Assay development, compound logistics and Screening facilities on par with what might be found 
in small and medium Biotechnology organisation
•Assay biology and targets originate from Institutional or regional networks (eg Max Planck), 
Scottish Universities etc) but also free to bring in external targets from other institutions
•Large libraries > 200k  and facilities to profile (ADME, tox, Med-chem, Computational)
•Diverse, fragment and focussed sets with emphasis on small molecules
•Integrated robotics and workstation based infrastructures
•Emphasis on drug discovery (eg tropical diseases) as well as Chemical Biology
•Staff led typically by experienced ex-Pharma scientists
Pan European Initiatives on horizon
Implementation  Phase Oct 2011 Implementation 2013 
http://imi.europa.eu
http://www.eatris.eu/
http://www.eu-openscreen.eu/
European Lead factory
Scale will be less than MLP, but still order of magnitude > than previous efforts (ChemBioNet etc)
Implementation  2013/2014
ESP Centralized Screening Hub
Compound 
Management
HTS System
Target +
Biol. IP
Project Basic Funding by
Funding BMBF and Shareholders 
Validated Hit:
•xC50
•Cytotox
•Cyp P450
•Apoptosis
•Biol. IP + Chem. IP
Chemistry
Evotec Library
• 250.000 cpds
• Proven track
record
ESP Library
• proof of concept /
known drug library
• Joint academic
ChemBioNet
ViSoR
• Virtual system for
molecular docking
ESP infrastructure
Infrastructure Services
Project development:
• Funding support
• Grant applications
• Build up consortia
Project prosecution:
• Assay  
Development
• Screening (prim., 
sec., HC, fragment
based)
• Hit ValidationIn Operation August 2008
Microsoft Office 
PowerPoint Presentation
Chemical Libraries at ESP
• Access to Evotec Library
• Σ = 250,000 compounds (cpds)
• Enamine Library hosted  
• Σ = 200,000 compounds (cpds) (70% diverse, gene and target family 
including PPI’s)
• ESP Library 
• Σ = 35,000 compounds (NP’s, lead-
like synthetic, 10% blinded)
• Access to Hypha Discovery
• Σ = 10,000 compounds 
1Evotec small molecule library
R small molecule13
Access to Evotec Library
•Σ = 250,000 compounds (cpds)
•20k Additional fragment based library
•All cpds QC-checked (LC/MS)
•Optimized cpd storage for long term stability
•Proven enhanced hit-rate from focussed 
sets
•Cpd design guided by Lipinski’s Rule-of-Five 
and knowledge-based filters to enhance drug 
likeness
•Privileged scaffolds and drug-like 
functionality complimented with extensive use 
of proprietary building blocks
•More than 40 different structural cpd classes
•Cpd preparation via validated, synthetic 
routes ensuring rapid access to analogues
ESP Library  - Blinded
• 2000 compounds Natural products and synthetic 
molecules from a German research Institute
• 300 compounds  - anti infectives from a German 
research Institute
• Future – an additional 1000 marine derived Natural 
products from a German research Institutes
These compounds have a less straightforward IP 
position but are available for screening in all projects 
Hypha Discovery Library
Case Study 1 North American University 
Indication Neurodegenerative disease
Target Protease
•Assay development
• Using full length protein substrate 
• TRF readout with antibody detection of cleavage site
• enzyme titration, kinetics of substrate turnover, standard 
compound profiling
• DMSO tolerance, day-to-day and plate-to-plate variability
•HTS campaign
• Primary screen 23k compounds
• Hit Confirmation in Primary 11pt dose response
• Hit characterization 2 additional orthogonal assay formats
• Secondary assay 1 – Luminescence 
• Secondary assay 2 - Fluorescence
Protein substrate [µM] log10 [inhibitor] M
Substrate Km
5µl assay volumeTR- FRET signal TR-FRET signal
Z’
TR-FRET signal
Z’
Screening and Profiling 23k cpds
Pharmacology DMSO tolerance
Screen StatsPrimary screenSecondary screens
Lumi Fluor
1.1% Hit rate @ 30% cut - off
Case Study 2 German Research Institute 
Indication Malaria
Target Synthesis of an essential co-factor
Assay development
• Hetro-dimer complex
• Coupled detection of synthase
product
• Enzyme titration and kinetics, (no 
standard compounds)
• DMSO tolerance, day-to-day and 
plate-to-plate variability
HTS campaign
• Primary screen 250k compounds
• Hit Confirmation 2500 compounds
• Hit Profiling 512 compounds
• Secondary assay parasite 
proliferation assay in human rbc’s (Safety Level 3) 
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DMSO ToleranceMarker Mini-screen
384 well Plates 
screened
945 (plus DMSO 
sacrificial plates)
Plate QC 
failures
104
Median Z’ 0.72    
Screened cpds 251,000
Hit Rate 1.4% (3607)
Confirmation
Pick size
2500
Primary Screening Statistics
•Compound Triage by expert Medicinal Chemist  
• Structural classification and selection based on potency and attractiveness as 
starting points
• Prioritized hits from known drug library to facilitate re-purposing
BE
C
Confirmation and Counter Assay
Counter Assay 1
• Detection system only
• 1uM Glutamate 
•>50% Compounds 
inhibit detection system
• Crucial readout
Putative Hits
Inhibit ors of 
detection
Confirmation assay
• Primary in triplicate
•80% Hit recovery
•Significant  # “super” 
inhibitors – artefacts?
Counter Assay  2
• Run reaction as primary 
• Add compound   then read
•Quenchers false +ve
•Fluorescent false -ve
• Resorufin produces robust 
signal!
Fluorescent 
cpds Quenching
cpds
Dose Response + Hit profiling
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Compound
Primary Assay  - 497 compounds (of 512) with curve fits
Counter  Assay - 200 compounds (of 512) with curve fits (IC-50 Primary) / (IC-50 Counter)    
Marine Fungi Project – Drug discovery
24.09.2013 Marine Fungi - WP7 MGA 
May 2012
23
The aim is to identify specific marine fungi derived compounds which are suitable
starting points for drug discovery. Parties in Drug Discovert Worrking groups: ESP,
GEOMAR, UIO (Oslo), DTI (Denmark), Hypha discovery (UK)
Cell line panel
• NCI cell line panel
24.09.2013 Marine Fungi - WP7 MGA 
May 2012
24
sourced all 60 cell lines
Preliminary panel consisting of 
M14, 786-0, MCF-7 and HL-60
 cell culture protocols set up
for 20 cell lines
Efficacy assessment assays at 3 sites
• Profile compounds effects on growth and viability of 
NCI panel
24.09.2013 Marine Fungi - WP7 MGA 
May 2012
25
ESP UIO HD
Cell Titer Glo Luminescence Viability Assay 
(Promega Corp., US)
Neutral Red Assay
toluylene red
stains lysosomes in living cells
Methods
24.09.2013 Marine Fungi - WP7 MGA 
May 2012
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 NCI cancer cell line screen
Concentrations at 50% cell growth (GI50), 0% cell 
growth (TGI) and -50% cell growth (LC50) were 
collected for each cell line per compound.
Aim: Screening of interesting compounds in the whole panel to 
obtain GI50, TGI and LC50 in each cell line 
Optimisation of protocols
• 3D cell culture (BioLevitator)
24.09.2013 Marine Fungi - WP7 MGA 
May 2012
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SF-593 A549-ATCC
M14 786-0
Bioinformatics tools for Cpd 
analysis
24.09.2013 Marine Fungi - WP7 MGA 
May 2012
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data
GI50
TGI
LC50
COMPARE
online tool
NCI
Mean
graph
Output
Correlation
of test 
compounds 
to known 
compounds
MoA
studies
Target 
directed
studies
NCI Mean Graph TGIs of compound 954 in 8
cell lines displayed relative to the mean (MG
MID) of -4.48 log molar . Unit: log molar
Assay Validation
24.09.2013 Marine Fungi - WP7 MGA 
May 2012
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 NCI cancer cell lines
Cell growth inhibition and Cytotoxicity assay validated for 17 cell 
lines
 Validation includes:
- DMSO tolerance
- Titration/Linearity experiments
- Signal stability experiments
- Cell growth evaluation
- Standard compound dose-response experiments
(cisplatin, paclitaxel, staurosporine, 6-mercaptopurine)
 Selected fractions and pure compounds screened in 
preliminary panel and all other validated cell lines
Purified compound – Example results
24.09.2013 Marine Fungi - WP7 MGA 
May 2012
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About 300 compounds screened in the 
preliminary panel
Hits identified and profiled in 17 cell lines 
(ESP&UIO)
• Compound A
Dose-response curve
compound 525n in SF-539
24.09.2013 Marine Fungi - WP7 MGA 
May 2012
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Profiling results (DRC)
pure compounds
mean graphs in all screened cell 
lines for COMPARE algorithm
Mean graph of compound B in 8 cell lines
Purified compound studies
Marine Fungi Project 
24.09.2013 Marine Fungi - WP7 MGA 
May 2012
32
Project on track to deliver in-vitro Proof of Concept (2013)
1H 2012
2013 2011 / 2012
2011
ESP Enabling Technologies group
Partner with Bioassay Discovery Tools Company (USA)
Validation of new reagent portfolio for epigenetic targets
 
H D ACS and thei r i nhibiti ons in c ancer cells  (Witt et al; Canc er L etters  277 (2009); 8-21)
Chuang et al ; Trends  in 
Neuros c .; Vol 32, No 11, 
591-601
H D AC inhibitiors  i n CNS di sorders 
(Kaz ants ev, Thompson; Nature Rev. 
D rug D is c.  Oct 2008;  Vol  7;  854-868)
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p53, MyoD,  
E2F -1, Stat3, 
androgen
cerv ic al  c ancer cells  :  H DAC1 knoc k down res ults  in i nhibiti on 
of proliferati on and i nducti on of autophagy ; os teos arcoma 
and breas t c anc er cell s : k noc kdown c aus es  cell  cy cl e arres t,  
growth i nhibiti on, apoptosi s;  c olon c ancer cells  :  knock down 
suppres ses  growth; pros tate c ancer:  ov erexpress ion increases 
prol iferation and dedifferentiati on; neurobl as toma cell s: 
knock down sensi tiz es  for chemotherapy ; CLL  c ells  : 
knock down sensi tiz es  for TRAIL apoptos is
Rett Sy ndrome
ac c umulating ev idenc e 
supports  the notion that 
his tone hy poac etyl ation 
and transc ri ptional 
dy sfunction are i nv ol ved 
in a large number of 
neurodegenartiv e 
c onditi ons  in v iv o and in 
v itro; targeti ng  his tone 
ac etylati on may prov ide 
benefi t for the treatment 
of depress ion,  
sc hi zophrenia, drug 
addic tion and anx iety  
dis orders ; Rubinstei n-
Taybi s yndrome: 
ubiqui tous  roles  of CBP 
and p300 in al l tiss ues , 
and the rec ent data 
suggesting
an improvement in long-
term memory  and 
s ynapti c pl as tic ity by  the 
H DAC i nhibitor tric ho-
s tati n A (TS A) through its 
effect on CBP and CREB; 
Friedreic h’ s atax ia : 
ex pans ion of a  tri pl et 
repeat reg ion wi thi n an 
intron in the frataxi n 
gene (F XN ),  whi ch 
enc odes a hi ghly  
c ons erved mitoc hondri al 
protein, l eads to 
trans cript-i onal  s ilenc ing 
i n the neuro-
degenerativ e di seas e
Friedreic h’s atax ia  (s ee 
Benz amide H DAC 
inhibitors);  F ragil e X 
syndrome:  benz ami de-
bas ed H DAC i nhibitors  
rev ersed frataxi n-
medi ated s ilenc ing,  S IRT1 
inhi bi tion revers es  
hetero-chromati n-
medi ated s ilenc ing of the 
F MR1 loc us  by increasi ng  
ac etyl ati on and 
dec reas ing methyl ation 
of his tones.  Therefore, 
pharmaco-l og ic al  
i nhibiti on of S IRT1 c oul d 
provide an a lternativ e 
s trategy to reac tiv ate 
F MR1 ex pres si on and to 
rev erse the los s of a 
requi red neuronal  
protein; a ls o involv ed i n 
Stroke,  H unti ngton' s 
di seas e, ALS , SMA, 
Parkins ons di seas es,  
Al zhei mers  dis eas e
embryonic  lethal day  9.5, p21 and p27 
upregulation, reduc ed ov erall  H DAC 
ac tiv ity
2 Y Y Y
Bcl -6, S tat3, 
g lucoc ortic oi d, 
rec eptor, YY-1
cerv ic al  c ancer cells : H DAC2 k noc kdown res ul ts  in 
di fferentiation,  apoptosi s and p53 independent p21 
ex press ion;  breas t c anc er cell s: increased p53 acti vi ty , 
inhi bi tion of prol iferation, induction of senes cence, i nduc ti on 
of apoptos is ; c olon c anc er c el ls:  k nock down c auses  growth 
arrest; neurobl as toma cells  :  k nock down induc es  apoptos is ; 
genetic H DAC2 mutation reduc es  intestinal  tumor 
dev el opment i n APC mic e i n vi vo; CL L c ells  : knock down 
sensi tiz es  for TRAIL-apoptos is
Rett Sy ndrome, S pi nal Mus cular Atrophy  
(S MA)
viable unti l perinatal peri od, fatal  
muli tple,  c ardiac  defec ts , exc ess iv e 
hy perplasi a of heart mus cle, arry thmi a
3 Y Y Y
G ATA-1, RelA, 
S tat3, MEF2D, 
YY-1,  S HP
APL  c ell s:  H DAC3 as soc iated with PML -RARa fusi on protei n,  
knock down induc es  differentiation genes ; AML :
AML -1-ETO binds HDAC3 (and HDACs  1, 2),  di srupts  c el l c yc le
embryonic  lethal before day 9. 5, 
defective c ell c y cl e, DN A repai r and 
apoptosi s in embry onic  fibroblas ts.  
Conditional l iver knoc k  out results i n 
hepatocy te and i nduc ti on of metaboli c 
genes hy pertrophy
8 Y Y Y nd
neuroblas toma c ells  : H DAC8 k noc kdown i nduc es 
di fferentiation,  c ell c y cl e arres t and inhibits c lonogenic  
growth; lung, c olon, cerv ic al  c ancer cells  :  knock down of 
H DAC8 reduces proli feration
Rett Sy ndrome nd
IIa
4 Y Y
G CMa,  G ATA-1,  
H P-1
APL  c ell s : H DAC4 interacts  wi th PL ZF-RARa fus ion protein, 
repres ses  differentiation genes ; renal c arci noma cells : 
knock down inhi bi ts ex pres s ion and func tional ac tiv ity of H IF -
1a
viable, premature and ec topic  
os si fic ation,  chondrocy te hypertrophy ; 
from the related c ardi ac
field, i t is  noteworthy  that k noc kdown of 
HDAC4 reduc ed i nfarc t si ze foll owing  
my ocardia l i sc hemia-induc ed 
reperfusi on i njury  
5 Y Y S mad7, H P-1, 
G CMa
erythroleukemia : HDAC5 s huttles  from nuc leus  to c y toplas m 
upon differenti ation, interacts wi th G ATA-1
seems  to mediate antidepres sant activ ity  
in animal s tudies  (N a-Buty rate)
my ocardia l hypertrophy , abnormal 
cardiac s tres s respons e
7 Y Y F LAG  1 and 2
endothelia l cells : HDAC7 s ilencing  a lters  morphology , 
migration and tube-formi ng  c apaci ty
embryonic  lethal , l ac k of endothelia l 
cell-cell  adhes ion
9 Y nd nd
viable at birth, spontaneous  my ocardia l 
hy pertrophy
IIb
6 Y Y
a-Tubul in, 
H S P90, S H P,  
S mad7
Targeted i nhibiti on of H DAC6 l eads  to ac etylati on of H S P90 
and disrupti on of i ts chaperone function, resulting i n 
depletion of pro-growth and pro-s urv ival cl ient proteins  
incl uding the Bc r-Abl  onc oprotein i n K562 l eukemic  c el ls;  
H DAC6 targeting  bloc k s EG F  induc ed nuc lear transl oc ation of 
ß-cateni n and c-myc  express ion in c olon c arc inoma c ells ; 
knock down of H DAC6 caus es donwregul ation of HI F-1a, 
VEG F R1/2; HDAC6 inv ov led in TG F b induc ed epi theli al -
mes enc hy mal  transi tion of lung c arc inoma cell s
viable, no si gnifi cant defec ts , i nc reas e in 
global  tubuli n ac etylati on. MEF s fai l to 
rec over from ox idativ e stres s
10 Y H S P90 ? Knock down of H DAC10 downregulates VEG FR nd
IV 11 nd nd nd
III
SI RT1 Y Y i nhibited inhi bited i nhibited fragi le X sy ndrome
SI RT2 Y i nhibited inhi bited
SI RT3 inhi bited
SI RT4 inhi bited
SI RT5 inhi bited
SI RT6 inhi bited
SI RT7 inhi bited
cl inic al tri al  phases
I, I I, III , 
appro
v ed 
CTCL
II , I II I,  II I I II I, I I I, I I
in 
c linic a
l tri al s 
for 
treatm
ent of 
S MA
l eukemia, advanc ed solid 
tumors, ly mphomas
nd:  no data
MEF:  mous e embry onic  fi broblasts
s trong inhibition (EC50 < 5fold EC50 relativ e to most sensitiv e HDAC isoform
weak  i nhibiti on (EC50 > 5fol d EC50 rel ati ve to mos t s ens itiv e H DAC is oform
no inhi bition (EC50 > 100fold EC50 relativ e to mos t s ens itiv e H DAC is oform
no data publi shed
Epigenetic targets  
ESP Library  
ESP Infrastructure  
ESP Expertise  
Novel assay
Limited validation
Enzyme (nM)
Industrialised format
HTS compatibility 
Market Validation  
Open Innovation in Practice:
Neu2  - A Competence Consortium in MS
Neu2 Project flow
Neu2  - Competence Cascade
Positioning of Neu2 portfolio
Neu2  Project portfolio April 2012
Activities
•Hit Finding – Phase  II trial 
•ScreeningPort involved in 3 running 
projects
•2 new MS Biomarker related projects 
accepted for next round
•1 new target for  comprehensive Hit 
finding
Scope and project finances
•Acute focus on Multiple Sclerosis
• Novel mechanisms favoured
• Higher risk than typical portfolio
• BMBF 25Mio first 3 years
• all projects need counter-financing
• No “double funding” allowed
•Renewal process mid 2012, goal is to 
secure additional 3 – 5 years funding 
Summary
• Pharma companies are increasingly moving out of early 
Discovery being replaced by Universities and Biotech
• Academic drug discovery is a vibrant activity, but the 
impact in terms of addressing unmet patient needs has yet 
to be fully realised
• Sources of compounds for Hi finding and Lead identification 
is increasingly varied and natural products still have a 
significant role to play
• Academia should not try to replicate Industry activities, 
rather to complement and be prepared to take on greater 
risks
